139 results
8-K
EX-10.3
OPNT
Opiant Pharmaceuticals Inc
15 Nov 22
Entry into a Material Definitive Agreement
4:22pm
8-K
EX-10.2
OPNT
Opiant Pharmaceuticals Inc
15 Nov 22
Entry into a Material Definitive Agreement
4:22pm
8-K
EX-10.4
OPNT
Opiant Pharmaceuticals Inc
15 Nov 22
Entry into a Material Definitive Agreement
4:22pm
8-K
EX-10.1
OPNT
Opiant Pharmaceuticals Inc
15 Nov 22
Entry into a Material Definitive Agreement
4:22pm
8-K
EX-10.1
sn0jitvi
13 Dec 21
Departure of Directors or Certain Officers
4:01pm
8-K
EX-10.1
c2p635f pkgck5up33bv
12 Jul 21
Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer
4:05pm
8-K
EX-10.1
0nz4qa qhj6oro2m
22 Mar 21
Departure of Directors or Certain Officers
4:05pm
8-K
EX-10.1
f92l6peacd5
14 Dec 20
Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
4:41pm
8-K
EX-10.1
yyx c16yt16q7zop
10 Dec 20
Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing
4:09pm
8-K
EX-10.1
4969wxqjgwcm91f
12 Nov 20
Results of Operations and Financial Condition
4:33pm
8-K
EX-10.1
oauf9
29 Oct 20
Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment
4:06pm
8-K
EX-10.1
wd41 n2no3
28 Jul 20
Entry into a Material Definitive Agreement
4:04pm
8-K
EX-10.1
squ9jii9ds jm
28 Dec 18
Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi
4:01pm
8-K/A
EX-10.86
33fvo7
4 Dec 18
Financial Statements and Exhibits
4:02pm
8-K
EX-10.1
fs3gflfm
30 Oct 18
Departure of Directors or Certain Officers
12:00am
8-K
EX-10.86
e8kelr8cvlh
20 Sep 18
Entry into a Material Definitive Agreement
4:20pm
8-K
EX-10.84
3xe1hhp xr02m
10 Sep 18
Entry into a Material Definitive Agreement
12:00am
8-K
EX-10.85
0zyvytkk6bf6pul 8k1y
10 Sep 18
Entry into a Material Definitive Agreement
12:00am